Alpha Genesis

Executive Summary

Alpha Genesis Inc. is a leading nonhuman primate (NHP) contract research organization (CRO) and breeding facility based in Yemassee, South Carolina, founded in 1999. The company provides purpose-bred NHPs, customized housing, and CDC-approved quarantine services, operating under GLP, USDA, OLAW, and AAALAC-compliant standards. With a focus on neuroscience and rare disease research, Alpha Genesis serves pharmaceutical and biotech clients requiring high-quality animal models for preclinical studies. As a private company in the pre-clinical stage, it has established itself as a reliable partner in the NHP supply chain, which has faced significant demand due to increased research in areas such as Alzheimer's, Parkinson's, and gene therapies. The company's integrated model—combining breeding, quarantine, and research services—provides a controlled environment that reduces variability and ensures regulatory compliance, making it a preferred vendor for both academic and commercial investigators. Alpha Genesis's strategic position is strengthened by the ongoing scarcity of NHPs globally, driven by export restrictions and rising R&D activity. Its adherence to rigorous standards (AAALAC, OLAW, USDA) and CDC-approved quarantine facilities offer clients a seamless transition from import to study initiation. The company is well-poised to capture market share as demand for NHP models continues to outpace supply. While financial details are undisclosed, the recurring revenue from breeding and services, along with long-term contracts, suggests a stable business model. However, risks include regulatory changes affecting NHP trade and potential competition from other breeders or CROs. Overall, Alpha Genesis represents a critical infrastructure provider in the preclinical neuroscience and rare disease ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Facility Expansion to Increase Breeding Capacity70% success
• Q2 2026Major Contract Win with a Top-20 Pharma Company50% success
• Q4 2026Launch of New CDC-Approved Quarantine Service80% success